Original Research

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

Kongnakorn T, Sterchele JA, Salvador CG, Getsios D, Mwamburi M

ClinicoEconomics and Outcomes Research 2014, 6:141-149

Published Date: 1 April 2014